Larger tumor size and more advanced tumor stage are associated with an increased risk of intravesical recurrence among patients undergoing radical nephroureterectomy for in upper tract urothelial carcinoma.
Adjuvant platinum-based chemotherapy for upper tract urothelial carcinoma within 90-days of nephroureterectomy improves disease-free and metastasis-free survival compared with surveillance, a study found.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
Find detailed treatment options for prostate cancer, including clinical trials and anticancer agents such as docetaxel, prednisone, and sipuleucel-T.
View a cancer treatment regimen chart for bladder cancer, including recommended neoadjuvant and adjuvant chemotherapy options.
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.
